The global market for Systemic Psoriasis Therapeutics was valued at USD 31.5 Billion in 2024 and is projected to reach USD 50.1 Billion by 2030, growing at a CAGR of 8.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Global Systemic Psoriasis Therapeutics Market - Key Trends and Drivers Summarized
How Are Advances in Psoriasis Treatments Addressing Systemic Conditions?
Systemic psoriasis therapeutics have transformed the management of psoriasis by targeting the underlying causes of the disease rather than just the symptoms. Systemic treatments are typically used for patients with moderate to severe psoriasis and include biologics, small molecule drugs, and systemic immunosuppressants. Biologics, which target specific components of the immune system responsible for inflammation, have gained significant traction due to their efficacy and ability to manage the condition long-term. With advancements in understanding the genetic and immunological underpinnings of psoriasis, newer biologics and other targeted therapies are providing better outcomes and improving patients' quality of life.What Technological Innovations Are Driving Psoriasis Treatment?
Technological advancements, particularly in biotechnology and pharmacogenomics, are reshaping the landscape of systemic psoriasis therapeutics. Biologics, which are genetically engineered proteins derived from human genes, have been developed to specifically inhibit the immune pathways involved in psoriasis, such as TNF-alpha inhibitors and interleukin inhibitors. Additionally, small molecule drugs targeting specific proteins within immune cells are emerging as a promising treatment option. Advances in precision medicine are also enabling more personalized treatment plans, as genetic and biomarker profiling allow physicians to identify the most effective therapies for individual patients based on their genetic predispositions.Which Patient Segments and Markets Are Driving Demand for Systemic Psoriasis Therapies?
The demand for systemic psoriasis treatments is growing across various patient demographics and geographies, with a significant uptick in developed markets such as North America and Europe. However, the increasing incidence of psoriasis in emerging markets in Asia-Pacific, driven by factors such as rising urbanization, lifestyle changes, and environmental triggers, is also contributing to market expansion. Additionally, systemic treatments are becoming the preferred option for patients with moderate to severe psoriasis who have not responded well to topical or phototherapy treatments. The rise of biologics and the approval of newer therapies have significantly expanded the treatment options available to these patients.What Is Fueling the Growth of the Systemic Psoriasis Therapeutics Market?
The growth in the systemic psoriasis therapeutics market is driven by several factors, including the increasing prevalence of psoriasis, particularly in urban areas, and the growing availability of advanced biologics and small molecule drugs. The expanding adoption of biologics, improved diagnostic capabilities, and greater awareness of the condition among healthcare providers and patients are key growth drivers. Additionally, the significant investments by pharmaceutical companies in R&D to develop more effective and safer therapies are driving innovation in this space. Favorable regulatory environments, government initiatives for better patient care, and advancements in personalized medicine further support the market's growth.Report Scope
The report analyzes the Systemic Psoriasis Therapeutics market, presented in terms of market value (USD Thousand). The analysis covers the key segments and geographic regions outlined below.Segments
Drug Class (TNF Inhibitors, Interleukin Inhibitors, Other Drug Classes); Route of Administration (Parenteral, Oral, Topical).Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.Key Insights:
- Market Growth: Understand the significant growth trajectory of the TNF Inhibitors segment, which is expected to reach $18.5 Billion by 2030 with a CAGR of a 8.8%. The Interleukin Inhibitors segment is also set to grow at 8.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $8.7 Billion in 2024, and China, forecasted to grow at an impressive 7.5% CAGR to reach $7.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in USD from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie Inc., Amgen Inc., Biogen Idec, Celgene Corporation, Eli Lilly and Company and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Systemic Psoriasis Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Systemic Psoriasis Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Systemic Psoriasis Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 38 major companies featured in this Systemic Psoriasis Therapeutics market report include:
- AbbVie Inc.
- Amgen Inc.
- Biogen Idec
- Celgene Corporation
- Eli Lilly and Company
- Janssen Biotech, Inc.
- Novartis AG
- Pfizer Inc.
- Stiefel Laboratories, Inc.
- Takeda Pharmaceutical Company Limited
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- Biogen Idec
- Celgene Corporation
- Eli Lilly and Company
- Janssen Biotech, Inc.
- Novartis AG
- Pfizer Inc.
- Stiefel Laboratories, Inc.
- Takeda Pharmaceutical Company Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 192 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 31.5 Billion |
| Forecasted Market Value ( USD | $ 50.1 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
